

Managing patients ahead of the Levemir discontinuation

Levemir products are being discontinued in December 2026. Patients need to be switched to suitable alternatives as soon as possible and in line with the guidance below.



What has happened

- Novo Nordisk is discontinuing Levemir (insulin detemir) FlexPen 100units/ml solution for injection 3ml pre-filled pens and Levemir (insulin detemir) Penfill 100units/ml solution for injection 3ml cartridges.
- Levemir is licensed in the treatment of Type 1 and Type 2 diabetes in adults, adolescents and children aged 1 year and above.
- Medicines Supply Notifications have been issued outlining important guidance for clinicians.
- Many patients still remain on Levemir products and require switching.



What clinicians need to do

- **Do not** initiate new patients on any Levemir product.
- **Implement insulin switches** for all existing Levemir patients in line with the guidance developed by the Association of British Clinical Diabetologists and the Primary Care Diabetes & Obesity Society.
- **Consult** the NHS SPS Medicines Supply Tool for up to date information regarding the availability of alternative treatments. **Some products, such as Humulin I and Abasaglar, cannot support uplifts in demand.**



Full information about the discontinuation and the actions healthcare professionals need to take can be found in the ABCD/PCDO guidance, which you can access via the QR code.